Funding for this research was provided by:
ADSCC (not applicable)
Received: 30 January 2021
Accepted: 7 April 2021
First Online: 28 April 2021
: The study was approved by the Emirates Institutional Review Board for COVID-19 Research (ID Ref: DOH/CVDC/2020/1172). In accordance with the Declaration of Helsinki, study participants provided written informed consent (World Medical Association Declaration of Helsinki: Ethical Principles for Human Medical Research [Internet]. Vol. 310, JAMA-Journal of the American Medical Association. JAMA; 2013 [cited 2020 Oct 18]. P. 2191–4. Available from: ExternalRef removed). In the informed consent document, the importance of participation was highlighted and the characteristics of the study and the possible risks and benefits were explained. All data were kept confidential and the identity of the participants was unlinked. Additional data is available by sending an email to the corresponding author. The selection of diagnostic tools followed the ethical principles of maximum benefit and non-maleficence. This manuscript has the approval of the ethical committee concerning publishing data derived from the main clinical trial.
: The patients signed the consent with full knowledge of it, as well as its risks and benefits; additionally, they approved the disclosure of laboratory results and images, as long as the protection of personal data was ensured.
: None of the contributing authors have any conflicts of interest.